The breast cancer cell lines treated with LY2835219 showed a concentration-dependent inhibition of pRb, and corresponding arrest of cells in G1 phase, which inhibited proliferation and led to decreased cell number 72. This evidence concerns the gene RB1 and breast carcinoma.